Want to see TELA full AI Analyst Report?
TELA Stock Chart & Stats
$0.70
-$0.04(-5.93%)
At close: 4:00 PM EDT
$0.70
-$0.04(-5.93%)
Day’s Range― - ―
52-Week Range$0.50 - $1.52
Previous Close$0.65
Volume24.70K
Average Volume (3M)219.51K
Market Cap
$43.80M
Enterprise Value$69.25M
Total Cash (Recent Filing)$30.42M
Total Debt (Recent Filing)$56.61M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Nov 11, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding45,143,410
10 Day Avg. Volume141,115
30 Day Avg. Volume219,506
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)8.78
Price to Sales (P/S)0.69
P/FCF Ratio-1.93
Enterprise Value/Market Cap1.58
Enterprise Value/Revenue0.87
Enterprise Value/Gross Profit1.28
Enterprise Value/Ebitda-2.10
Forecast
1Y Price Target
$1.75Price Target Upside150.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.68
Revenue Forecast (FY)$79.58M
Bulls Say, Bears Say
Bulls Say
Revenue Scale And Gross MarginThe multi-year revenue increase demonstrates meaningful commercialization progress, while consistently strong gross margins indicate attractive product economics. Together, these characteristics provide a platform for operating leverage if TELA can convert its established portfolio and clinical adoption into sustained profitable growth.
International ExpansionInternational growth provides geographic diversification and shows that TELA’s hernia portfolio is gaining traction beyond its domestic market. A broader customer and procedure base can support longer-term revenue durability, reduce dependence on any single market, and create additional opportunities for portfolio adoption.
New Product OptionalityLiora expands TELA’s soft-tissue reconstruction portfolio with a fully resorbable synthetic implant and adds a new product platform alongside OviTex. In-house development and production may strengthen product control and give the company another avenue for surgeon adoption and future commercial growth.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the business is not yet funding itself through operations. Combined with deep net losses, this increases reliance on cost reductions or external financing, limits strategic flexibility, and makes execution on the growth plan more important over the coming quarters.
Strained Balance SheetElevated debt alongside negative equity materially weakens TELA’s financial cushion. This structure can constrain investment in commercial expansion, increase sensitivity to operating shortfalls, and leave fewer options for managing obligations while the company works toward sustainable profitability and positive cash generation.
Commercial Execution PressureGuidance withdrawal and the sharp PRS decline signal reduced visibility into near-term demand and execution. Longer sales-force ramp times can delay productivity and revenue recovery, while weakness in a key product line may prolong losses and force further cost reductions before growth becomes dependable.
TELA Bio News
TELA FAQ
What was TELA Bio’s price range in the past 12 months?
TELA Bio lowest stock price was $0.50 and its highest was $1.52 in the past 12 months.
What is TELA Bio’s market cap?
TELA Bio’s market cap is $43.80M.
When is TELA Bio’s upcoming earnings report date?
TELA Bio’s upcoming earnings report date is Nov 11, 2026 which is in 20 days.
How were TELA Bio’s earnings last quarter?
TELA Bio released its earnings results on Aug 10, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.174 by -$0.026.
Is TELA Bio overvalued?
According to Wall Street analysts TELA Bio’s price is currently Undervalued.
Does TELA Bio pay dividends?
TELA Bio does not currently pay dividends.
What is TELA Bio’s EPS estimate?
TELA Bio’s EPS estimate is -0.16.
How many shares outstanding does TELA Bio have?
TELA Bio has 45,143,410 shares outstanding.
What happened to TELA Bio’s price movement after its last earnings report?
TELA Bio reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.174. Following the earnings report the stock price went down -15.054%.
Which hedge fund is a major shareholder of TELA Bio?
Currently, no hedge funds are holding shares in TELA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TELA Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.75 (150.00% Upside)
$1.75 (150.00% Upside)
Blogger Sentiment
Bullish
TELA Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $96.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.35%
12-Months-Change
Fundamentals
Return on Equity
1248.13%
Trailing 12-Months
Asset Growth
-11.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
TELA Bio
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
TELA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of operational positives (12% unit growth, strong international performance, LIQUIFIX momentum, improved gross margin and leadership changes) but was dominated by near-term commercial execution issues: a revenue miss (-4% YoY), a sharp PRS revenue decline (~24%), ASP/mix pressure, extended sales ramp timelines, higher interest expense, and withdrawal of full-year guidance. Management outlined concrete remediation steps (leadership upgrades, training programs, market access improvements, cost reductions) and expressed confidence in second-half recovery, but near-term financial and competitive headwinds are material.View all TELA earnings summariesTELA Stock 12 Month Forecast
Average Price Target
$1.75
▲(150.00% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
NeuroOne Medical Technologies
―
Pulmonx
―
Icecure Medical
―
Ownership Overview
22.22% Insiders
4.87% Mutual Funds
50.01% Other Institutional Investors
19.49% Public Companies and
Individual Investors